
Stocks rise, euro firms after US-EU trade agreement
The U.S. struck a framework trade agreement with the European Union, imposing a 15% import tariff on most EU goods - half the threatened rate, a week after agreeing to a trade deal with Japan that lowered proposed tariffs on auto imports.
Countries are scrambling to finalise trade deals ahead of an August 1 deadline set by U.S. President Donald Trump, with talks between the U.S. and China set for Monday in Stockholm amid expectations of another 90-day extension to the truce between the world's top two economies.
"A 15% tariff on European goods, forced purchases of U.S. energy and military equipment and zero tariff retaliation by Europe, that's not negotiation, that's the art of the deal," said Prashant Newnaha, senior Asia-Pacific rates strategist at TD Securities. "A big win for the U.S."
S&P 500 futures rose 0.4% and the Nasdaq futures gained 0.5% while the euro firmed across the board, rising against the dollar, sterling and yen. European futures surged nearly 1%.
MSCI's broadest index of Asia-Pacific shares outside Japan (.MIAPJ0000PUS), opens new tab was up 0.27%, just shy of the almost four-year high it touched last week. Japan's Nikkei fell 0.8% after hitting a one-year high last week.
While the baseline 15% tariff will still be seen by many in Europe as too high, compared with Europe's initial hopes to secure a zero-for-zero tariff deal, it is better than the threatened 30% rate.
The U.S.-EU deal provides clarity to companies and averts a bigger trade war between the two allies that account for almost a third of global trade.
"A major tail-risk has now been defused," said Marc Velan, head of investments at Lucerne Asset Management in Singapore.
"Markets are interpreting this as a sign of stability and predictability returning to trade policy," he added. "The China delay fits the same pattern: the administration is opting for controlled diplomacy over confrontation."
China's blue-chip stocks (.CSI300), opens new tab rose 0.3% while the Hong Kong's Hang Seng index (.HSI), opens new tab advanced 0.75%.
The Australian dollar , often seen as a proxy for risk appetite, was at $0.657, hovering around the near eight-month peak scaled last week.
In an action-packed week, investors will watch out for the monetary policy meetings from the Fed and the BOJ as well as the monthly U.S. employment report and earnings from megacap companies Apple (AAPL.O), opens new tab, Microsoft (MSFT.O), opens new tab and Amazon (AMZN.O), opens new tab.
While the Fed and the BOJ are expected to maintain rates, comments from the officials will be crucial for investors to gauge the interest rate path. The trade deal with Japan has opened the door for the BOJ to raise rates again this year.
Meanwhile, the Fed is likely to be cautious on any rate cuts as officials seek more data to determine tariffs' impact on inflation before they ease rates further.
But tensions between the White House and the central bank over monetary policy have increased, with Trump repeatedly lashing out at Fed Chair Jerome Powell for not cutting rates. Two of the Fed Board's Trump appointees have articulated reasons for supporting a rate cut this month.
"Inflation readings, particularly the PCE index, and the upcoming July jobs report will shape expectations beyond this meeting, with the next likely policy pivot now pushed out to September if inflation continues to ease," said Kieran Williams, head of Asia FX at InTouch Capital Markets.
In commodities, oil prices rose after the U.S.-EU trade agreement. Brent crude futures and U.S. West Texas Intermediate crude both rose 0.5%.
Gold prices fell on Monday to their lowest in nearly two weeks on reduced appetite for safe havens.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
10 minutes ago
- Reuters
Russia-backed Nayara taps Indian IT firm as Microsoft suspends service, sources say
NEW DELHI, July 29 (Reuters) - Russia-backed Indian refiner Nayara Energy, recently sanctioned by the European Union, has turned to domestic firm after tech giant Microsoft (MSFT.O), opens new tab suspended services, three sources familiar with the matter said. Nayara, which has condemned the sanctions, said on Monday it had filed a case against U.S.-based Microsoft in the Delhi High Court over its withdrawal of services. The sources spoke on condition of anonymity as they were not authorised to speak to media. Nayara and Rediff did not immediately respond to requests for comment. Incorporated in 1996, Rediff India, headquartered in the commercial capital of Mumbai, aims to provide world-class online consumer service offerings, from news and email to an online shopping marketplace, the company says on its website.


Reuters
10 minutes ago
- Reuters
AstraZeneca beats profit expectations on robust drug sales, U.S. demand
July 29 (Reuters) - AstraZeneca (AZN.L), opens new tab beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from President Donald Trump. The beat is a boost for the drugmaker as the wider sector braces for U.S. tariffs on pharmaceutical imports and navigates pricing challenges after Trump's order pushing for prices in the U.S. to fall to what other countries pay. The firm's shares rose around 1% in early trading on Tuesday. AstraZeneca, the UK's largest-listed company by market value, in April had forecast only a limited impact from potential U.S. tariffs on pharmaceutical imports, and said it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-U.S. trade deal over the weekend will result in a 15% tariff on pharmaceuticals from the region. The Anglo-Swedish drugmaker, which is targeting $80 billion in annual revenue by 2030, maintained its annual outlook and increased its interim dividend by 3%. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Sales of AstraZeneca's oncology drugs, which make up nearly half of its revenue and are being weighed down by changes in U.S. Medicare price negotiations, were up 18% at $6.31 billion at constant currency rates for the three-month period ended June 30. Analysts at Jefferies said sales of key cancer drugs such as Tagrisso, Lynparza, Calquence, and Truqap and Imfinzi were ahead of expectations. Total revenue grew 11% to $14.46 billion, with core earnings of $2.17 per share, with double-digit growth in the U.S., which makes up more than 40% of sales. That compares with analysts' expectations of $14.15 billion and $2.16, respectively, according to a company-provided consensus. AstraZeneca, which is hoping to move on from scandals in its second-biggest market, China, where it also faces minor fines related to cancer drugs, said it was also fighting several patent challenges from an individual against Tagrisso.


Spectator
39 minutes ago
- Spectator
France is turning against the EU
When Donald Trump won a second term in the White House last November the response in Europe was one of barely disguised horror. 'The European Union must stand close together and act in a united manner,' declared Germany's Chancellor Olaf Scholz. Emmanuel Macron posted a message on X: 'The question we, as Europeans, must ask ourselves is, are we ready to defend the interests of Europeans?' The president of France got his answer on Sunday evening. No. The trade deal agreed between Ursula von der Leyen, the EU Commission president, and Donald Trump has not gone down well in much of Europe. Scholz's successor, Friedrich Merz forecast that Germany's economy would suffer 'significant' damage because of the deal. EU exports will have a tariff of 15 per cent, which is superior to the customs duties before Trump's re-election, but much lower than his threatened 30 per cent tariff. Additionally, von der Leyen has promised the bloc will purchase energy worth $750 billion from the United States and make $600 billion in additional investments. According to Hungary's Viktor Orban: This is not an agreement… Donald Trump ate von der Leyen for breakfast.' The most strident criticism of the deal came from France, where in a rare display of unity the terms of the agreement were savaged across the political spectrum. Prime Minister Francois Bayrou said that 'it is a dark day when an alliance of free peoples, united to assert their values and defend their interests, resigns itself to submission.' Trade minister Laurent Saint-Martin described the deal as unbalanced and said the government should not accept 'what happened yesterday because that would be accepting that Europe is not an economic power.' It was telling that Saint-Martin said 'Europe' and not 'France'. For centrists like Saint-Martin – he was one of the first to join Macron's fledging En Marcheparty in 2016 – France and the EU are indistinguishable. Macron's predecessor (and mentor), Francois Hollande once accused him of 'believing in nothing and having no conviction'. That is not true. Macron has one unshakeable conviction and that is the EU. It is why he won't let Brexit go, taking every opportunity to savage Britain's decision to leave the bloc. Twice during his recent state visit he went on the attack. Britons were 'sold a lie' over Brexit he said at one point, adding on another occasion that the country 'was stronger when part of the EU.' As yet there has been no response the Elysee to von der Leyen's trade deal. Perhaps Macron is still working out how best to spin the fact that Britain's tariff rate with the USA is 10 per cent. Marine Le Pen lost little time in pointing this out, posting on X that the EU 'has obtained worse conditions than the United Kingdom.' The leader of the National Rally described the deal as 'a political, economic and moral fiasco' and said that that 'this form of globalisation, which denies and destroys sovereignty, has been outdated for many years.' The majority of the French agree with her. In an interview with the BBC in 2018, Macron admitted that if given the choice his people would probably follow Britain out of the EU. This is one reason why he has been so determined to make life difficult for post-Brexit Britain: pour encourager les autres. Macron's strategy has been partially successful. A poll last year revealed that 62 per cent of the French are opposed to Frexit. The bad news for the president is that 69 per cent of them have a bad opinion of the EU. The poll was conducted a month before the European elections, which resulted in a resounding victory for Le Pen's Eurosceptic party and a humiliating defeat for Macron's Europhile movement. When Le Pen reached the second round of the 2017 presidential election it was with a promise to quit the EU. Two years later she abandoned that position and vowed to reform the bloc from within. Her party won't return to Frexit but it will increase its Euroscepticism between now and the 2027 election. The same goes for the hard-left's Jean-Luc Melenchon, who loathes Brussels as much as Le Pen. Bruno Retailleau, the leader of the centre-right Republicans, is also a long-standing critic of the EU's ambition and voted against the EU Constitution in France's 2005 referendum. That result, he said in a 2020 interview, along with Brexit, 'have shown one and the same thing: Europeans do not want a federal Europe.' Across France enmity towards the EU has strengthened in the last year. The Mercosur trade deal agreed with South America in December is widely unpopular and France's failure to control its borders is blamed on Brussels. The French are demoralised and angrier than ever with their ruling elite. A citizens' collective called 'Bloquons tout!' (Block everything) is using social media to mobilise people for a day of protest on September 10. 'Boycott, disobedience, and solidarity' is their rallying cry and they are urging people to take to the streets across France. Will it achieve anything? Probably not. After all, what's the point of protesting in Paris when all the big decisions about France's future are made in Brussels.